Oncoheroes Biosciences’ Pediatric Cancer Drug Candidate Receives Orphan Drug Designation

Oncoheroes Biosciences, a biotech focused on advancing new therapies for childhood cancer, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to its lead candidate, volasertib, for use in treating pediatric rhabdomyosarcoma and other rare soft tissue sarcomas.

Read more: https://oncoheroes.com/press-releases-content/2020/10/14/volasertib-a-potential-new-treatment-for-rhabdomyosarcoma-receives-orphan-drug-designation-from-the-us-fda?ss_source=sscampaigns&ss_campaign_id=5f865ac9a6719d48ca49acb5&ss_email_id=5f873934dbbf7b61e83af6f5&ss_campaign_name=NEWS%21+FDA+grants+now+Orphan+Drug+Designation+to+volasertib&ss_campaign_sent_date=2020-10-14T17%3A46%3A09Z